On March 5, 2026, Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, announced the closing of an oversubscribed $105 million Series C financing round. Wilson Sonsini Goodrich & Rosati advised Cognito Therapeutics on the transaction.

The round was led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with participation from new investors New Vintage, Apollo Health Ventures, and Benvolio Group, among others.

The financing will assist Cognito Therapeutics’ advancements toward pivotal data readout, regulatory submission, and commercial launch, while supporting continued clinical development of its Spectris^™device designed to treat neurodegenerative diseases like Alzheimer’s and preparation efforts ahead of an anticipated market entry in 2027. The funding will also support advancement of the Spectris platform into additional neurodegenerative indications through their network of brain health collaboratories.

The Wilson Sonsini team that advised Cognito Therapeutics on the transaction included Mark Fitzgerald, Aaron Gordon, Daniel Jordan, Alex Stebbins, and Taylor Yi.

For more information, please see Cognito Therapeutics’ news release. Additional coverage can be found on Fierce Biotech, MobiHealthNews, Pharmaceutical Executive, and Medical Device Network.